Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Recommendation of “Buy” by Analysts

Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) have been given an average recommendation of “Buy” by the eight brokerages that are covering the firm, MarketBeat Ratings reports. Six analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $21.71.

ZVRA has been the topic of a number of analyst reports. Guggenheim set a $21.00 target price on Zevra Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, February 4th. Cantor Fitzgerald upgraded Zevra Therapeutics to a “strong-buy” rating in a research note on Wednesday, January 29th. HC Wainwright reiterated a “buy” rating and issued a $20.00 price target on shares of Zevra Therapeutics in a research note on Wednesday, November 20th. Finally, Canaccord Genuity Group decreased their price target on Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating for the company in a research note on Thursday, November 14th.

Insider Buying and Selling

In other Zevra Therapeutics news, CEO Neil F. Mcfarlane sold 61,273 shares of Zevra Therapeutics stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $7.86, for a total transaction of $481,605.78. Following the transaction, the chief executive officer now directly owns 222,060 shares in the company, valued at approximately $1,745,391.60. The trade was a 21.63 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Joshua Schafer sold 10,500 shares of Zevra Therapeutics stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $7.86, for a total transaction of $82,530.00. Following the transaction, the executive vice president now owns 29,486 shares in the company, valued at approximately $231,759.96. The trade was a 26.26 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 85,773 shares of company stock valued at $674,176 over the last quarter. Corporate insiders own 2.40% of the company’s stock.

Hedge Funds Weigh In On Zevra Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vestal Point Capital LP purchased a new position in Zevra Therapeutics during the 3rd quarter worth approximately $3,644,000. Geode Capital Management LLC grew its holdings in shares of Zevra Therapeutics by 14.2% during the 3rd quarter. Geode Capital Management LLC now owns 1,043,864 shares of the company’s stock valued at $7,246,000 after acquiring an additional 129,600 shares in the last quarter. Barclays PLC grew its holdings in shares of Zevra Therapeutics by 292.6% during the 3rd quarter. Barclays PLC now owns 57,599 shares of the company’s stock valued at $399,000 after acquiring an additional 42,926 shares in the last quarter. Propel Bio Management LLC purchased a new position in shares of Zevra Therapeutics during the 3rd quarter valued at $1,248,000. Finally, Simplify Asset Management Inc. purchased a new position in shares of Zevra Therapeutics during the 3rd quarter valued at $833,000. 35.03% of the stock is currently owned by hedge funds and other institutional investors.

Zevra Therapeutics Stock Up 0.9 %

Shares of NASDAQ ZVRA opened at $8.07 on Wednesday. Zevra Therapeutics has a 1 year low of $4.20 and a 1 year high of $9.76. The firm has a market cap of $430.74 million, a price-to-earnings ratio of -4.10 and a beta of 1.98. The company has a debt-to-equity ratio of 0.84, a quick ratio of 2.88 and a current ratio of 2.88. The stock’s 50-day simple moving average is $7.96 and its 200-day simple moving average is $8.14.

Zevra Therapeutics (NASDAQ:ZVRA) last announced its earnings results on Tuesday, March 11th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.28). Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. The business had revenue of $12.00 million for the quarter, compared to analysts’ expectations of $8.93 million. As a group, equities analysts anticipate that Zevra Therapeutics will post -1.95 earnings per share for the current fiscal year.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.